Ocera Therapeutics Inc (NASDAQ:OCRX)
Traders News Source issued a comprehensive analysis on Ocera Therapeutics Inc (NASDAQ:OCRX). Earlier in this month, the company reported that it would release an update from its Phase IIb STOP-HE trial of intravenous OCR-002 in hospitalized subjects with Hepatic Encephalopathy at the popular Cowen and Company Yearly Healthcare Conference. In the month of January, it already reported from its Phase I trial of orally given OCR-002 in subjects with chronic liver cirrhosis.
As of now, there are no drug therapies for HE that can be administered intravenously to hospitalized people with acute HE. OCR-002 is rapidly advancing to be an extremely encouraging ammonia scavenger treatment being explored for HE. Additionally, this formulation is being advanced both as intravenous and oral treatment, and is targeting a market size of almost $2 billion in the U.S.
OCR-002 has been given orphan drug status and Fast Track designation by the U.S. FDA, which indicates that it will enjoy seven years of market exclusivity. Ocera Therapeutics Inc (NASDAQ:OCRX), a clinical stage biopharmaceutical firm focused on chronic and acute orphan liver diseases, was founded by John C. Kappes, Eckard Weber and Wu Xiaoyun in 1998.
The firm’s business risk profile can derive considerable strength from the encouraging competitive landscape, growing market size in HE division, superior clinical profile of ‘OCR-002’, numerous modes of drug administration, and increased probability of getting reimbursement. Additionally, Biotech as a division is displaying enormous strength in 2017 and is supported by a support in overall Merger and Acquisition activities, the expectations for considerable tax and regulatory reform, and election outcome.
As a product of which, shareholders are extremely bullish about the prospective development for this orphan liver disease player. Additionally, on March 10, Ocera Therapeutics Inc (NASDAQ:OCRX) reported its fourth quarter and also full fiscal 2016 financial report. It posted a net loss for the quarter and year closed December 2016 at $5.2 million and $26.9 million, correspondingly. As of the close of December 2016, the cash/cash equivalents and investments stood at $28.4 million.
Zacks Investment Research upgraded Ocera Therapeutics Inc (NASDAQ:OCRX) to a “buy” rating from a “hold” rating. The firm has a $1.50 target price on the firm’s stock. This target price suggests a potential upside of 25% from the firm’s current price. It also comes on the basis considering management expects that it holds sufficient cash to support operations into Q2 2018.
|Last Price a/o 3:21 PM EST||$1.25|
|Market Cap (mlns)||$29.46M|
|Shares Outstanding (mlns)||23.57M|
|Share Float (mlns)||23.13M|
|Short Interest Ratio||0.32|
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.